Skip to main content

Table 2 Number and share (%) of assessed and reimbursed orphan drugs by type of HTA recommendation, by country

From: The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe

Countrya

Assessed orphan drugs (out of 101)

Assessed orphan drugs

Reimbursed orphan drugs

Positive

Conditional

Negative

Assessed orphan drugs

Not assessed orphan drugs

Total number

Out of 101

Out of assessed drugs

Positive

Conditional

Negative

England

20 %

20

60 %

12

5 %

1

35 %

7

13

13 %

65 %

25 %

3

0 %

0

14 %

1

11 %

9

Germany

25 %

25

100 %

25

0 %

0

0 %

0

20

20 %

80 %

76 %

19

0 %

0

0 %

0

1 %

1

Poland

36 %

36

19 %

7

36 %

13

44 %

16

23

23 %

64 %

71 %

5

69 %

9

31 %

5

6 %

4

Netherlands

38 %

38

13 %

5

74 %

28

13 %

5

30

30 %

79 %

20 %

1

75 %

21

40 %

2

10 %

6

Sweden

43 %

43

95 %

41

0 %

0

5 %

2

41

41 %

95 %

100 %

41

0 %

0

0 %

0

0 %

0

Scotland

60 %

61

51 %

31

2 %

1

48 %

29

11

11 %

18 %

19 %

6

0 %

0

10 %

3

5 %

2

Wales

67 %

68

28 %

19

9 %

6

63 %

43

13

13 %

19 %

32 %

6

0 %

0

12 %

5

6 %

2

France

74 %

75

85 %

64

9 %

7

5 %

4

20

20 %

27 %

30 %

19

0 %

0

25 %

1

0 %

0

  1. Source: Authors’ own calculations based on information from the websites of the eight HTA agencies
  2. Notes: aCountries ordered according to the share of assessed orphan drugs (from lowest to highest)